Australia weighs AI medical scribes: regulators assess safety, privacy, and incentive risks

Australian health regulators are examining AI-powered medical scribes as adoption among doctors surges, flagging concerns over patient privacy, consent, transcription accuracy, and contested revenue claims. The outcome could shape how similar AI documentation tools are governed in Australia and beyond.

What happened

The Australian government is urging healthcare professionals to exercise caution when using AI-powered medical scribing tools, as regulators examine whether stronger safeguards are needed. According to documents obtained by The Guardian Australia through freedom of information requests, the federal health department has identified several risks associated with AI scribing tools. Briefing papers prepared for Senate Estimates in February 2026 describe the technology as having "little oversight" and note that some AI scribes are marketed as operating outside existing medical device regulations despite being used in clinical settings.

Adoption is surging. An online survey conducted by the Royal Australian College of General Practitioners (RACGP) found that the proportion of Australian doctors using AI scribes nearly doubled from 22 percent in August 2024 to 40 percent by November 2025. Technology providers also claim their platforms have processed hundreds of millions of consultations globally over the past 18 months.

Why AI builders should care

For teams building AI documentation tools for healthcare, the Australian review signals that regulators are paying close attention to governance gaps. The core issues are not unique to Australia: privacy, consent, accuracy, and accountability apply to any market where AI scribes are deployed.

Transcription and summarisation errors could affect patient safety and data quality. The health department warns that these tools inherit many of the same limitations as large language models. Errors in transcription or summarisation could affect patient safety, clinical accountability, and the quality of information stored in Australia's digital health infrastructure.

The regulatory approach could also influence how similar AI documentation tools are classified and governed. The Therapeutic Goods Administration (TGA) is currently reviewing whether AI scribes should be formally classified as medical devices, a decision that could bring many platforms under stricter regulatory oversight.

Practical implications

Clinics may need clearer patient consent processes when recording consultations for AI scribes. The government found significant variation in how clinics obtain permission before recording consultations, arguing that meaningful informed consent requires patients to understand both the benefits and limitations of AI-assisted documentation. Consumer groups have reported instances where patients were told they would need to find another healthcare provider if they declined to have AI scribes used during appointments.

Data transmission is another concern. Officials found that some providers promote their products as privacy compliant while offering limited transparency about how patient information is processed. In some cases, healthcare providers may not even realise patient data is being transmitted to cloud servers outside Australia, potentially exposing sensitive medical information to additional risks.

The department also questioned marketing claims suggesting AI scribes can increase doctors' revenue by around 30 percent without extending working hours or seeing more patients. Officials noted that such claims could have broader implications for Australia's publicly funded Medicare system if higher billing becomes a primary incentive for adoption.

Caveats

Evidence on the regulatory stance is evolving. The source material relies on government briefings obtained by The Guardian Australia and an RACGP survey, and may not reflect final classifications or approvals. The TGA is expected to release a report in the coming months.

Marketing claims of revenue gains are contested and could have broader Medicare implications if adopted widely without corresponding patient safeguards. The regulatory landscape remains fragmented, with oversight currently shared between the TGA, the Australian Health Practitioner Regulation Agency (Ahpra), and the Office of the Australian Information Commissioner.

FAQs

What are AI medical scribes and how are they used in Australian clinics?

AI medical scribes record, transcribe, and summarise doctor-patient conversations into clinical notes, reducing the administrative burden on healthcare workers. Regulators are assessing safeguards for privacy, consent, and transcription accuracy as adoption grows. An RACGP survey found that usage among Australian doctors rose from 22% in August 2024 to 40% by November 2025.

Are AI scribes compliant with Australian privacy laws and patient consent requirements?

Officials have raised concerns about data transmitted to cloud servers outside Australia and varying consent practices. Some providers promote their products as privacy compliant while offering limited transparency about how patient information is processed. The government found significant variation in how clinics obtain permission before recording consultations.

How are regulators assessing AI scribes for medical device classification in Australia?

The Therapeutic Goods Administration (TGA) is reviewing whether AI scribes should be formally classified as medical devices. Oversight is currently shared with the Australian Health Practitioner Regulation Agency (Ahpra) and the Office of the Australian Information Commissioner. A decision is expected in the coming months.

What privacy risks are associated with AI scribes sending data to cloud servers outside Australia?

There are concerns that patient data may be transmitted to foreign cloud servers, potentially exposing sensitive medical information to additional risks. Officials found that some healthcare providers may not even realise patient data is being transmitted to cloud servers outside Australia.